Incyte to Acquire Villaris Therapeutics and Auremolimab (VM6)

AbbVie to Acquire ImmunoGen for $10.1 Billion

November 30, 2023

Pharmaceuticals

AbbVie entered into a definitive agreement to acquire ImmunoGen, including its flagship ADC therapy ELAHERE (mirvetuximab soravtansine-gynx), in a deal valued at approximately $10.1 billion. The transaction is expected to close in mid-2024, subject to ImmunoGen shareholder approval, regulatory approvals, and other customary closing conditions.

Novartis AG Acquires Calypso Biotech BV

January 9, 2024

Pharmaceuticals

Calypso Biotech BV, focused on IL-15 targeted therapies for autoimmune diseases, agreed to be acquired by Novartis AG. Under the deal terms, Calypso shareholders will receive an upfront payment of $250 million at closing plus potential development milestones of up to $175 million.

Vertex Pharmaceuticals to Acquire Alpine Immune Sciences

April 10, 2024

Biotechnology

Vertex Pharmaceuticals entered into a definitive agreement to acquire Alpine Immune Sciences for $65 per share in cash, valuing the deal at approximately $4.9 billion. The transaction is unanimously approved by both boards and is anticipated to close later in the second quarter of 2024.

BioVie Acquires Biopharma Assets of NeurMedix

June 11, 2021

Pharmaceuticals

BioVie Inc. acquired the biopharmaceutical assets of privately held NeurMedix, including NE3107, an orally administered small-molecule inhibitor targeting neuroinflammation and insulin resistance. The deal paid NeurMedix shareholders newly issued BioVie shares and cash at closing, with additional contingent cash and equity payments tied to clinical and regulatory milestones; the acquisition expands BioVie's pipeline into neurodegenerative diseases and oncology.

Cosette Pharmaceuticals Acquires Vyleesi from Palatin Technologies

January 3, 2024

Pharmaceuticals

Cosette Pharmaceuticals, a U.S. specialty pharmaceutical company backed by Avista Healthcare Partners, has acquired the Vyleesi (bremelanotide) product and related intellectual property from Palatin Technologies. The deal transfers five Orange Book-listed patents (protection through 2041) and aims to expand Cosette’s women's health portfolio while ensuring continued patient access during the transition.

Sanofi to Acquire Blueprint Medicines to Expand Rare Immunology Pipeline

June 2, 2025

Pharmaceuticals

Sanofi and Blueprint Medicines entered into an agreement under which Sanofi will acquire Blueprint via a cash tender offer and subsequent merger. The deal values Blueprint at $129.00 per share in cash (approximately $9.1 billion equity value), with additional potential milestone payments tied to BLU-808 via a contingent value right.